Brief: Anika Therapeutics Q2 Revenue USD 28.219 Million

Anika Therapeutics

30/07/2025 12:06

Overview

Anika Therapeutics Q2 rev falls 8% yr/yr but beats analyst expectations, per LSEG data

Regenerative Solutions rev up 41%, driven by Integrity Implant System

Hyalofast trial misses primary endpoints; shows improvement in secondary measures

Outlook

Company maintains 2025 revenue guidance for Commercial and OEM Channels

Anika updates 2026-2027 guidance due to Hyalofast launch delay

Company expects US OA Pain Management pricing decline in H2 2025

Anika plans Hyalofast PMA module submission in H2 2025

Result Drivers

REGENERATIVE SOLUTIONS - Revenue increased 41% driven by Integrity Implant System and strong Hyalofast growth

INTEGRITY IMPLANT - Surpassed full year 2024 performance and is on pace to more than double in 2025

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$28.22 mln
$27 mln (3 Analysts)
Q2 Net Income
-$3.97 mln
Q2 Gross Profit
$14.36 mln
Q2 Income from Operations
-$4.18 mln
Q2 Pretax Profit
-$3.97 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Anika Therapeutics Inc is $21.00, about 46.9% above its July 29 closing price of $11.16

Press Release: ID:nGNXbSLNLG

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)